OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. The company is headquartered in Ewing, New Jersey and currently employs 40 full-time employees. The company went IPO on 2015-05-29. The firm is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec Medical System EP device (the OMS EP Device) and a DNA plasmid delivery and application method that enables transient expression of recombinant therapeutic molecules in cells. The OMS EP Device is designed to promote cellular uptake of plasmid DNA injected directly into solid tumors to allow subsequent expression of the encoded therapeutic protein. The OMS EP Device can be adapted to treat different tumor types and consists of an electrical pulse generator and a disposable applicator. Its lead product candidate, tavokinogene telseplasmid (TAVO), is a plasmid encoding human interleukin-12.

Industry: Pharmaceutical Preparations Peers: Corbus Pharmaceuticals Holdings Inc Viskase Holdings Inc Aceragen, Inc. Immix Biopharma Inc Indaptus Therapeutics Inc Monopar Therapeutics Inc THERALINK TECHNOLOGIES, INC. Vaccinex Inc